Ascendis Pharma (ASND) said its supplemental biologics license application for TransCon hGH as therapy for adult growth hormone deficiency was accepted for review by the US Food and Drug Administration.
The FDA has set a July 27 review deadline, the company said Thursday in a statement.
The supplemental application is based on the results of a phase 3 trial that evaluated 259 adults with growth hormone deficiency, and TransCon hGH was found to be "generally safe and well tolerated," Ascendis said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments